Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aedifica NV (AED) Fair Value & Analysis

Real Estate · BE · Market cap €5.9B

Price€68.55
Fair Value€36.17
Upside-47.2%
Quality95/100
Evidence: High Range €21.82 – €48.14

Analysis

Aedifica NV (AED) currently trades at €68.55, while our model-based Fair Value estimate is €36.17 — implying the stock looks roughly 47.2% overvalued today. We read business quality at 95/100 (high quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Aedifica NV/SA is a Belgian public regulated real estate company specializing in European healthcare real estate, particularly properties for elderly care. Aedifica has built a real estate portfolio worth approximately 12.4 billion euros in Belgium, Germany, the Netherlands, the United Kingdom, Finland, Ireland, Spain, France, and Italy. Aedifica is listed on Euronext Brussels (2006) and Euronext Amsterdam (2019) and is identified by the following codes: AED; AED:BB (Bloomberg); AOO.BR (Reuters). Since 2020, Aedifica has been a constituent of the BEL 20, the main stock market index of Euronext Brussels. Furthermore, since 2023, Aedifica has been included in the BEL ESG, the index that tracks the best-performing companies based on ESG criteria. Aedifica is also included in the EPRA, Stoxx Europe 600, and GPR indices. Its market capitalization was approximately 5.7 billion euros as of May 18th, 2026. Aedifica NV/SA was established on November 07, 2005 and incorporated in 2005 in Belgium.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.